Hemodialysis Vascular Grafts Market 2018 - Global Industry Size, Market Trends, Growt
Hemodialysis Vascular Grafts Market is expected to reach US$ 285.2 Mn by 2026
End stage renal disease (ESRD) is a medical condition in which the kidney functions only 10% of its natural ability to perform excretion of toxic material from the human blood. When the glomerular filtration rate of the kidney is <15 ml/min/1.73 m2, patient is reported with end stage renal failure. Diabetes and hypertension are the chief causative factors in chronic kidney disease. Chronic kidney disease has a global prevalence rate between 11 to 13% in stage 3 ESRD. The role of vascular grafts in hemodialysis procedure is to attain blood flow from one area to the other by connecting blood vessels.
Polyurethane is mixed in different concentration to achieve vascular graft with improved tensile strength and larger inner luminal diameter to promote smooth blood transfusion during hemodialysis procedure. Polytetrafluoroethylene currently dominates the raw material segment for hemodialysis vascular grafts market. Its inherent features such as high adhesion, excellent native fistula pliability and reimburesemnt scenario drive the market growth. Bioengineered materials will be the latest trendsetter during the forecast period due to improved material characteristics which prevent infection, hemorrhage and graft rejection occurring during hemodialysis procedure in patients suffering with chronic kidney disease.
Download Sample research report with TOC and Figures @ https://www.credenceresearch.com/
With a market share of 36% North America is the largest regional market in hemodialysis vascular grafts market. The properties influencing its dominant growth are increasing geriatric population suffering with end stage renal disease and higher healthcare expenditure. Existence of market leaders such as C.R.Bard, Inc., Terumo Medical Corporation and CryoLife, Inc. etc. further propel the hemodialysis vascular grafts market in the North America region. Europe currently holds 28% share owing to features such as supportive reimbursement scenario associated with hemodialysis vascular grafts and increasing demand for hemodialysis procedures compared to intraperitoneal dialysis in patients suffering with chronic kidney disease. Asia Pacific represents 20% share and is set to engrave positive growth in the near future due to proactive government policies to fight renal disease and rapid growth in medical tourism.
Pharmaceutical companies manufacturing hemodialysis vascular grafts are C.R.Bard, Inc., CryoLife, Inc., Getinge AB., InnAVasc Medical, Inc., LeMaitre Vascular, Inc., Merit Medical Systems, Inc., Proteon Therapeutics, Inc., Terumo Medical Corporation, Vascular Genesis and W.L.Gore Associates.
Name: Chris Smith (Global Sales Manager)